• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解决 MAFLD:肝脏铁死亡的治疗靶点。

Ironing out MAFLD: Therapeutic targeting of liver ferroptosis.

机构信息

Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Suzhou Medical College of Soochow University, Soochow University, Suzhou, Jiangsu, China.

Liver Center, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Cell Metab. 2024 Oct 1;36(10):2167-2169. doi: 10.1016/j.cmet.2024.09.005.

DOI:10.1016/j.cmet.2024.09.005
PMID:39357507
Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with iron metabolism disorders and ferroptosis, but the mechanisms underlying this association remain unclear. Fudi Wang's group used animal models, human cohorts, and multi-omics data to demonstrate the role of iron imbalance in MAFLD and the therapeutic potential of the iron chelator FerroTerminator 1 (FOT1).

摘要

代谢相关脂肪性肝病(MAFLD)与铁代谢紊乱和铁死亡有关,但这种关联的机制尚不清楚。王府迪研究团队使用动物模型、人类队列和多组学数据,证明了铁失衡在 MAFLD 中的作用,以及铁螯合剂 FerroTerminator 1(FOT1)的治疗潜力。

相似文献

1
Ironing out MAFLD: Therapeutic targeting of liver ferroptosis.解决 MAFLD:肝脏铁死亡的治疗靶点。
Cell Metab. 2024 Oct 1;36(10):2167-2169. doi: 10.1016/j.cmet.2024.09.005.
2
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH.综合临床前研究确定 FerroTerminator1 是治疗 MASH 的有效药物。
Cell Metab. 2024 Oct 1;36(10):2190-2206.e5. doi: 10.1016/j.cmet.2024.07.013. Epub 2024 Aug 13.
3
Intermittent hypoxia exacerbates metabolic dysfunction-associated fatty liver disease by aggravating hepatic copper deficiency-induced ferroptosis.间歇性低氧通过加剧肝铜缺乏诱导的铁死亡加重代谢功能障碍相关脂肪性肝病。
FASEB J. 2024 Jul 15;38(13):e23788. doi: 10.1096/fj.202400840R.
4
Alisma Orientalis Extract Ameliorates Hepatic Iron Deregulation in MAFLD Mice via FXR-Mediated Gene Repression.泽泻提取物通过 FXR 介导的基因抑制改善 MAFLD 小鼠肝脏铁失调。
Nutrients. 2024 Jul 15;16(14):2272. doi: 10.3390/nu16142272.
5
Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis.铁死亡抑制剂 Liproxstatin-1 可缓解小鼠代谢相关脂肪性肝病:潜在涉及 PANoptosis。
Acta Pharmacol Sin. 2023 May;44(5):1014-1028. doi: 10.1038/s41401-022-01010-5. Epub 2022 Nov 2.
6
Si-Wu-Tang alleviates metabolic dysfunction-associated fatty liver disease by inhibiting ACSL4-mediated arachidonic acid metabolism and ferroptosis in MCD diet-fed mice.四物汤通过抑制ACSL4介导的花生四烯酸代谢和铁死亡来减轻MCD饮食喂养小鼠的代谢功能障碍相关脂肪性肝病。
Chin Med. 2024 Jun 6;19(1):79. doi: 10.1186/s13020-024-00953-7.
7
Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?铁死亡与代谢相关脂肪性肝病:有关联吗?
Liver Int. 2022 Jul;42(7):1496-1502. doi: 10.1111/liv.15163. Epub 2022 Jan 23.
8
Metabolomics analyses reveal the liver-protective mechanism of Wang's metabolic formula on metabolic-associated fatty liver disease.代谢组学分析揭示王氏代谢方对代谢相关脂肪性肝病的肝脏保护机制。
Heliyon. 2024 Jun 22;10(13):e33418. doi: 10.1016/j.heliyon.2024.e33418. eCollection 2024 Jul 15.
9
The gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxin-linked MAFLD.肠道微生物群代谢产物甘氨胆酸激活 TFR-ACSL4 介导的铁死亡,促进环境毒素相关 MAFLD 的发生发展。
Free Radic Biol Med. 2022 Nov 20;193(Pt 1):213-226. doi: 10.1016/j.freeradbiomed.2022.10.270. Epub 2022 Oct 17.
10
Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation.葛根素通过抑制铁死亡和炎症改善代谢功能障碍相关脂肪性肝病。
Lipids Health Dis. 2023 Nov 24;22(1):202. doi: 10.1186/s12944-023-01969-y.

引用本文的文献

1
Redox mechanism of glycerophospholipids and relevant targeted therapy in ferroptosis.铁死亡中甘油磷脂的氧化还原机制及相关靶向治疗
Cell Death Discov. 2025 Aug 1;11(1):358. doi: 10.1038/s41420-025-02654-y.
2
Mechanistic Elucidation of Polysaccharides in Treating MAFLD via Regulation of the Gut Microbiota-Metabolite-Ferroptosis Axis: A Multi-Omics Perspective.基于多组学视角解析多糖通过调节肠道微生物群-代谢物-铁死亡轴治疗MAFLD的机制
J Agric Food Chem. 2025 Jun 26. doi: 10.1021/acs.jafc.5c05877.
3
Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease.
河马-YAP1/TAZ信号通路在代谢功能障碍相关脂肪性肝病中的调控
Front Pharmacol. 2025 Jan 23;16:1505117. doi: 10.3389/fphar.2025.1505117. eCollection 2025.